Are peptides safe for someone in their 70s, 80s or 90s?

The short answer

The honest answer to "are peptides safe for a 74-year-old?" is that for most of the compounds people ask about, nobody knows, because nobody has tested it. That is not a hedge. It is the single most important fact on this page, and it is true in a specific, checkable way: the trials that would answer the question either were never run, or were run in people decades younger.

There is one partial exception. The approved GLP-1 drugs — semaglutide, tirzepatide — do have evidence in older adults, and that evidence contains a genuine warning worth understanding before anyone starts. Everything else in the peptide world, including every compound sold by research vendors, has no human safety data at any age, which means it has none at 70, 80 or 90 either.

Evidence tier: mixed. Tier 1–2 for the GLP-1 sections (randomised trials plus large cohorts). Tier 5 — no human data — for most other compounds, which is itself the point. Educational content, not medical advice.

Key points:

• Age changes the risk, not just the dose. Kidney and liver clearance decline, other
• Muscle loss is the central concern. In a cohort of adults 65+ with type 2 diabetes on
• Fracture risk shows a real signal. In over 46,000 adults aged 65+, GLP-1 users had a modest
• Dialysis changes the answer. The EU label for semaglutide says it is not recommended below
• For BPC-157, TB-500, epitalon, MOTS-c and the rest, there is no age-specific guidance because

Why the trials do not answer your question

Clinical trials routinely exclude the people asking this question. Upper age limits, exclusion of significant kidney or liver impairment, exclusion of people on many concurrent medications, exclusion of anyone with recent cardiovascular events — each is reasonable for the trial, and the combined effect is that the enrolled population looks very little like a 78-year-old on five medications.

A 2026 reappraisal of GLP-1 use in older adults made exactly this argument: prescribing should move toward a function-centred model accounting for frailty, sarcopenia and nutritional status, and future trials should actually enrol older, frailer participants. That recommendation only makes sense because they currently do not.

So when a marketing page says a compound is "well tolerated", the honest translation is "well tolerated in the people who were studied". If you are 80, you were almost certainly not among them.

The muscle question, which is the one most people are really asking

A large share of the questions we see are some version of "what peptide stops an older person losing muscle?" It is a good question, and the evidence points somewhere uncomfortable.

Sarcopenia — age-related loss of muscle mass and function — already affects roughly 18.8% of community-dwelling older adults, rising to about 28.5% among those with diabetes. That is the baseline before any drug is involved.

Weight lost on a GLP-1 is not all fat. Across recent trials, lean soft tissue has accounted for somewhere between 15% and 60% of total weight lost, varying by person and by drug. In younger people with plenty of reserve, that is a manageable trade. In someone already sarcopenic, losing a further slice of lean mass is not a cosmetic issue — it is grip strength, stair climbing, and getting up from a chair.

The most direct evidence comes from a 24-month retrospective cohort of adults aged 65 and over with type 2 diabetes taking semaglutide: muscle mass, handgrip strength and gait speed all declined relative to controls. That is observational, so it cannot prove the drug caused it. But gait speed is one of the better predictors of outcomes in older adults, and seeing it move in the wrong direction is not reassuring.

Alongside that, a population-based cohort of more than 46,000 adults aged 65+ found GLP-1 users had a modestly but significantly higher rate of fragility fractures than users of other glucose-lowering drugs (HR 1.11, 95% CI 1.01–1.21). The authors argued the signal should not be waved away. It is a small relative increase; at this age the absolute consequences of a hip fracture are not small.

What appears to help, with honest caveats: resistance training and adequate protein — roughly 1.2–1.6 g/kg/day — are the standard recommendations, and one randomised trial found that liraglutide combined with exercise preserved hip and spine bone density while liraglutide alone did not. That is a real randomised result and it is the strongest thing on this page in the "what to do" direction. But the trial testing resistance exercise and protein specifically during semaglutide or tirzepatide therapy (LEAN-PREP, NCT06885736) has not reported. Treat training and protein as the best available bet, not as a settled answer.

The uncomfortable implication: for an older adult who is already losing muscle, the question is not which peptide to add. It is whether losing weight pharmacologically is the right goal at all, and that is a conversation with a clinician who can measure rather than guess.

Kidneys, and the dialysis question

Someone searched our site asking whether peptides are safe for an 85-year-old woman on dialysis. It deserves a direct answer rather than a general one.

Kidney function declines with age even without disease, and most of the compounds people are asking about are cleared at least partly renally. For the two approved drugs where labels exist:

• Semaglutide (EU label): no dose change for mild or moderate impairment, but **not
• Tirzepatide: labelling does not require renal dose adjustment, including in end-stage renal

There is a second, more practical kidney risk that gets less attention: these drugs commonly cause nausea, vomiting and reduced intake. Dehydration is how a GLP-1 damages kidney function in practice — not through direct toxicity but through volume loss, and an older adult on a diuretic has less margin for that than most.

For everything that is not an approved drug, there is no renal guidance at all, because there are no human pharmacokinetic studies to base it on.

Everything else: why there is no answer, not a cautious answer

The compounds that dominate these questions — BPC-157, TB-500, epitalon, MOTS-c, thymosin fragments, GH secretagogues bought online — sit at evidence tiers 4 and 5 in our framework: animal and cell studies only, or no human data whatsoever.

This has a specific consequence that is easy to miss. When a page says a compound is "generally well tolerated in older adults", there is no study behind that sentence. There is no study behind a cautious version of that sentence either. The appropriate response to "is BPC-157 safe for a 90-year-old?" is not "probably, with care" — it is "that question has never been studied in anyone, at any age, in a controlled human trial."

Two things follow that matter more at 80 than at 40:

Polypharmacy. Interactions are unknown for compounds that have never been through interaction studies. Someone taking an anticoagulant, a beta blocker, a diuretic and a statin is adding an unstudied variable to a system with several moving parts, and nobody — including us — can tell you what it does.

Consequence asymmetry. A side effect that is an inconvenience at 40 can be a hospital admission at 85. Dizziness is a fall. A week of poor intake is a week of lost muscle that may not come back. The probability of harm may be similar; the cost of it is not.

What is worth asking a clinician

These are the questions that actually move the decision, and they work regardless of what is being proposed:

• Is this approved for my situation, or am I extrapolating? Approval attaches to a condition,
• What happens if I do nothing, over the same period? For many age-related complaints this is
• What are we measuring, and when? Grip strength, gait speed, weight, kidney function, and
• How does this interact with what I already take? Including whether anyone knows.
• If the goal is muscle or function, is a drug the right tool here? Resistance training has

Limitations

This is educational content, not medical advice, and nothing here is a reason to start or stop any medication.

• Most of the GLP-1 evidence in older adults is observational. Cohort studies cannot establish
• The fracture and muscle findings are modest in size. They are signals worth knowing, not
• Renal labelling differs by jurisdiction and changes. Check the current label for your country.
• We have deliberately not listed "best peptides for seniors". Not because we are being coy, but

The bottom line

For the approved GLP-1 drugs, there is real evidence in older adults, and it carries a specific warning: muscle, strength and gait speed appear to decline, and fracture risk is modestly elevated. That does not mean they should never be used after 70 — obesity carries its own serious risks — but it means the decision should involve measurement, resistance training, enough protein, and someone monitoring kidney function.

For everything else, the position is simpler and harder to hear. There is no safety data in older adults because there is no safety data in anyone. Age does not make an untested compound more dangerous in a way we can quantify; it makes the consequences of being wrong larger, and it removes the margin that lets a younger person absorb a mistake.

If you are 70 or 80 and someone is confidently telling you which peptides you should be on, the most useful thing you can ask them is where their evidence in people your age comes from.

Related on this site

• GLP-1 muscle preservation: what actually works
• GLP-1 complete guide
• Our evidence-tier framework
• Are peptides legal?
• GH peptides for muscle: the honest evidence
• Spotting counterfeit peptides

References

• Muscle and bone implications of GLP-1 receptor agonists and fragility fractures in older adults with diabetes. Journal of Cachexia, Sarcopenia and Muscle, 2026. — cohort of >46,000 adults aged 65+, fragility fracture HR 1.11 (95% CI 1.01–1.21).
• GLP-1 receptor agonists for obesity management in older adults: a scoping review on the risk of sarcopenia and sarcopenic obesity. Current Nutrition Reports, 2026. — limited and inconsistent muscle data; resistance exercise and 1.2–1.6 g/kg/day protein recommended.
• GLP-1 receptor agonist therapy and skeletal muscle: a narrative review synthesising adult evidence with implications for older adults, 2026. — evidence in older adults too limited to quantify vulnerability.
• Reappraisal of GLP-1 receptor agonists in older adults, 2026. — argues for function-centred prescribing and enrolment of older, frailer participants in trials.
• Sarcopenia prevalence: ~18.8% of community-dwelling older adults, ~28.5% among older adults with diabetes.
• 24-month retrospective cohort, adults 65+ with type 2 diabetes on semaglutide — declines in muscle mass, handgrip strength and gait speed versus controls.
• Semaglutide EU summary of product characteristics — not recommended at eGFR <30 mL/min/1.73m², including ESRD.
• Tirzepatide prescribing information and UK prescribing support material — no renal dose adjustment required, limited experience in severe impairment and ESRD, caution advised; age ≥85 listed under cautions.
• LEAN-PREP randomised trial of resistance exercise and protein during semaglutide/tirzepatide therapy, NCT06885736 — registered, not yet reported.